Regular Article
Identification and Regulation of Human PDE5A Gene Promoter

https://doi.org/10.1006/bbrc.2000.4220Get rights and content

Abstract

PDE5A gene encodes type 5 phosphodiesterase (PDE5), the principal cGMP-catalyzing enzyme in the penis and the primary target of sildenafil (Viagra). We have isolated a 3.7-kb DNA fragment that contains the human PDE5A gene promoter. The DNA fragment contains a sequence of 234 nucleotides at its 3′ end that corresponds to most of the untranslated region of the PDE5A1 mRNA. The remaining 3.5-kb upstream flanking sequence contains no apparent TATA box but has several sequences that resemble binding sequences for transcription factors such as androgen receptor (AR), AP1, AP2, AP4, Sp1, MyoD, Myc, and CArG. In search of promoter activities, we used a luciferase reporter system to examine 10 DNA fragments that cover various regions of the 3.7-kb fragment. We found that a full basal promoter activity was confined to a 139-bp region that includes 78 bp of the PDE5A1-specific first exon. A lesser basal promoter activity was still detectable in a 94-bp fragment that contains the same 78-bp PDE5A1-specific exon plus 16 bp of upstream sequence. Either the 139-bp or the 94-bp promoter fragment responded minimally to cAMP or cGMP (2 mM) stimulation. Longer fragments that contain either a 308-bp 5′ extension (from the 138-bp fragment) or a 156-bp 3′ extension (all exon sequence) responded at higher levels to cAMP and cGMP stimulation. The 5′ and 3′ extensions cooperated with each other to provide the highest level of responses to cAMP and cGMP stimulation. DNase I footprint analysis identified four AP2- and two Sp1-binding sites in the 5′ extension and four Sp1-binding sites in the 3′ extensions. Cyclic AMP and cGMP had similar stimulatory effects on the PDE5A promoter.

References (27)

  • C. Schudt et al.

    Pulmonary Pharmacol. Therapeutics

    (1999)
  • M.A. Movsesian

    J. Am. Coll. Cardiol.

    (1999)
  • L.M. McAllister-Lucas et al.

    J. Biol. Chem.

    (1993)
  • S.A. Ballard et al.

    J. Urol.

    (1998)
  • J.D. Corbin et al.

    J. Biol. Chemi.

    (1999)
  • C.S. Lin et al.

    Biochem. Biophys. Res. Commun.

    (2000)
  • C.S. Lin et al.

    Biochem. Biophys. Res. Commun.

    (2000)
  • C.S. Lin et al.

    DNA Cell Biol.

    (1997)
  • A.M. Maxam et al.

    Methods Enzymol.

    (1980)
  • P. Stacey et al.

    Biochem. Biophys. Res. Commun.

    (1998)
  • K. Loughney et al.

    Gene

    (1998)
  • J. Kotera et al.

    J. Biol. Chem.

    (1998)
  • T. Gudi et al.

    J. Biol. Chem.

    (1996)
  • Cited by (64)

    • Effect of Genetic Polymorphism on the Response to PDE5 Inhibitors in Patients With Erectile Dysfunction: A Systematic Review and a Critical Appraisal

      2020, Sexual Medicine Reviews
      Citation Excerpt :

      Thus, T786 C polymorphism at the eNOS locus appeared to be a major contributor in the variable erectile function PDE5Is/testosterone response. The PDE5A gene and its promoter regions have been sequenced and the functional regions are well described in humans.33,34 The presence of polymorphisms in PDE5A in humans has been linked to the reduced response to NO and altered levels of cGMP.35

    • Dysregulated NO/PDE5 signaling in the sickle cell mouse lower urinary tract: Reversal by oral nitrate therapy

      2019, Life Sciences
      Citation Excerpt :

      Decreased PDE5 activity in the urethra of Sickle mice is also evidenced by heightened urethral relaxation to an NO donor SNP (because the NO effector, cGMP, cannot be degraded). Low PDE5 activity is conceivably due to low NO bioavailability and absence of the cGMP-dependent feedback mechanism for PDE5 regulation [47,48]. A previous study described reduced protein expression of PDE5 in the bladder of male rats following bladder outlet obstruction-induced bladder overactivity, which has been speculated to be an adaptive response to decreased levels of cGMP; however, no functional relevance was suggested [49].

    • Genetics of NO Deficiency

      2017, American Journal of Cardiology
      Citation Excerpt :

      PDE5 is expressed in smooth muscle cells and is the pharmacologic target of vasodilatory drugs (such as PDE5 inhibitors) used to treat PH and erectile dysfunction.54 The coding sequence, functional regions, and transcript variants of PDE5A are well described.55,56 Genetic studies have identified PDE5A variants associated with PH and chronic heart failure.

    View all citing articles on Scopus

    Abbreviations used: PDE, phosphodiesterase; PCR, polymerase chain reaction; db-cAMP, dibutyryl cyclic AMP; db-cGMP, dibutyryl cyclic GMP; AR, androgen receptor; bp, base pairs; kb, kilobases.

    View full text